MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology (MURDOCH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04872309|
Recruitment Status : Recruiting
First Posted : May 4, 2021
Last Update Posted : June 10, 2022
Lung magnetic resonance imaging (MRI) with proton and inhaled inert gases has demonstrated a clinical ability to provide valuable structural and functional information in lung disease. Advances in lung MRI methods have led to the STH department handling clinical imaging referrals from local and national respiratory units. Hyperpolarised Xenon-129 gas MRI is now the gold-standard MRI modality used in clinical practice for asthma and COPD in Sheffield.
In this new study, the investigators will use Xenon gas MR imaging and 19F gas MR imaging to obtain physiological, structural, and functional information about patients with known respiratory disease, namely asthma and COPD. Up to 20 patients with asthma and up to 20 patients with COPD will be recruited. Study visits will involve lung function tests and imaging using proton MRI, hyperpolarised xenon gas MRI, and 19F perfluoropropane MRI. After initial baseline assessments, patients will be followed up after 3 and 6 years to investigate the utility of MRI and lung function measurements in tracking disease progression over time.
In addition, during the COVID-19 pandemic will also be studying the long term effects of this novel disease. The investigators will use Xenon gas MR imaging and pulmonary vascular 1H MR imaging to obtain physiological, structural, and functional information about patients with COVID-19, including hospitalised patients and mild, non-hospitalised COVID-19 patients. Participants may be invited for baseline assessments during the symptomatic phase of the disease and/or be followed up after 6, 12, 24 and 52 weeks (in line with clinical follow up for hospitalised patients) to investigate long term effects of this novel disease.
This novel approach will provide mechanistic insight in to clinical observations such as : (i) why previously healthy patients can respond so poorly to oxygen/ventilation therapy, (ii) why patients respond to proning, and (iii) whether this is caused by alveolar-capillary interstitial changes and /or microvascular clotting in the pulmonary vasculature (leading to V/Q mismatch), and (iv) whether these acute changes lead to long term interstitial lung disease.
|Condition or disease|
|Asthma COPD Covid19 Long COVID|
For asthma and COPD patients, this is a feasibility study to explore the use of gas MRI lung imaging techniques in tracking disease progression over a 6 year time period. Participants will have a baseline MRI scanning session and then be asked to come for repeat scans after 3 and 6 years.
Participants will attend for 3 visits, once at baseline, at 3years and 6 years. Each visit is split over 2 days should occur within one week. This is to ensure eligibility for MRI scanning.
At the eligibility visit the research team discuss study with patient and obtain informed consent. An MRI Screening Form is used to identify any contra-indications to MRI scanning. The participant will be asked further questions about their health, current diagnosis and any current treatments, smoking history, and about any exposure to pollutants either at home or at work. Women will be asked to take a urine pregnancy test, to ensure pregnant women are excluded from the study. The study doctor will perform a brief cardio-respiratory examination to check that it is safe for the patient to undertake the study. At the MRI scanning visit the participant will have a series of MRI scans, firstly using Xenon gas, then after a short break a they will have a second set of scans using 19F perfluoropropane gas. The participant will also undertake some simple lung function tests.
For COVID patients, this is pilot observational study using nationally unique MR imaging methods to investigate the acute and long-term pathophysiology of COVID-19 infection and the resulting changes seen in the lung, pulmonary vasculature and heart of patients with COVID-19 over the course of 12months.
Patients will attend for up to 5 visits. These are at baseline (patient may still be hospitalised, or this may be shortly after discharge) and 6, 12, 24 and 52 weeks post discharge. These visit timelines are designed to match with clinical follow up timelines for hospitalised patients. After the initial approach and consent patients will be screened for eligibility using the MRI scanning checklist. Patients who are still hospitalised or have significant ongoing respiratory problems will undertake a test gas inhalation under close supervision to ensure that this is tolerated prior to MRI scanning. A renal function blood test will be undertaken if required. For some non-hospitalised patients this will require an additional visit.
At the first MRI scanning visit consent will be taken or re-affirmed if taken prior to this visit. Medical history and medication check will be taken and women of child bearing age will undertake a pregancy test. The participant will have a series of MRI scans, firstly using Xenon gas, then after a short break a they will have a proton MRI which includes using gadolinium contrast. The participant will also undertake some simple lung function tests, including spirometry, gas transfer and endoPAT. Lung function tests will only be completed if the patient is non-infectious.
The repeat assessments at 6, 12, 24 and 52 weeks will be the same as the first visit, patients will be contacted prior to their repeat visit to repeat the MRI screening form and confirm eligibility.
|Study Type :||Observational|
|Estimated Enrollment :||160 participants|
|Official Title:||MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology|
|Actual Study Start Date :||September 4, 2019|
|Estimated Primary Completion Date :||August 2027|
|Estimated Study Completion Date :||August 2027|
Adults with physician diagnosis of stable asthma (BTS guideline Step 3 or above).
Adults with Stage 3 or 4 COPD (as defined by GOLD guideline 2018)
Adults who have been hospitalised on ICU with COVID-19 (requiring CPAP or mechanical ventilation)
Adults hospitalised with COVID-19
Mild- Non-hospitalised COVID-19
Adult with proven COVID-19 infection, not hospitalised for COVID-19
Non-hospitalised symptomatic (long-COVID group)
Patients presenting at secondary care clinics post COVID-19 with ongoing symptoms.
- %Ventilated volume [ Time Frame: 3-6 years for asthma/COPD patients, 3-12months for COVID-19 participants ]a measurement derived from MRI images that quantifies the relative amount of lung that is ventilated, corrected for size.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04872309
|Contact: Jim M Wild||+44 114 215 email@example.com|
|Academic Unit of Radiology, Univeristy of Sheffield||Recruiting|
|Sheffield, South Yorkshire, United Kingdom, S10 2SJ|
|Contact: Jim Wild, Professor +44 114 215 9141 firstname.lastname@example.org|
|Principal Investigator: Rod Lawson, Dr|
|Sub-Investigator: Ian Sabroe, Prof|
|Sub-Investigator: Roger Thompson, Dr|
|Sub-Investigator: Paul Collini, Dr|
|Sub-Investigator: Gary Mills, Prof|